Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies-Reference-Cited by-同舟云学术

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

Published:2024-04 Issue:4 Volume:27 Page:109363
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Inoue Tetsuya,Yamamoto Yuichiro^ORCID,Sato Kaoru,Okemoto-Nakamura Yuko,Shimizu Yoshimi^ORCID,Ogawa Motohiko^ORCID,Onodera Taishi^ORCID,Takahashi Yoshimasa^ORCID,Wakita Takaji,Kaneko Mika K.^ORCID,Fukasawa Masayoshi^ORCID,Kato Yukinari^ORCID,Noguchi Kohji^ORCID

Funder

AMED

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Reference98 articles.

1. Therapeutic strategies for COVID-19: progress and lessons learned;Li;Nat. Rev. Drug Discov.,2023

2. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab;Gupta;N. Engl. J. Med.,2021

3. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial;Self;Lancet Infect. Dis.,2022

4. Neutralizing monoclonal antibodies for treatment of COVID-19;Taylor;Nat. Rev. Immunol.,2021

5. Antibodies to combat viral infections: development strategies and progress;Pantaleo;Nat. Rev. Drug Discov.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain;Human Vaccines & Immunotherapeutics;2024-08-20

2. Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern;2024-05-06